03.12.2024 15:00:16
|
EQS-News: Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board
EQS-News: Viromed Medical AG
/ Key word(s): Personnel
Viromed Medical AG is expanding its Management Board – Christian Strauch has been appointed as a new member of the Management Board Pinneberg, 3 December 2024 – The Supervisory Board of Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”) has appointed Mr. Christian Strauch as a new member of the company's Management Board with effect from 1 January 2025. The previous sole member of the Management Board, Uwe Perbandt, has been appointed Chairman of the Management Board. "Viromed Medical AG is facing major challenges in the further research, application and global marketing of cold plasma technology. In order to meet these challenges efficiently and successfully, we need to spread the workload across a larger team. In Christian Strauch, we have found an outstanding and internationally experienced expert who, with his extensive know-how, can make a significant contribution to the success of the company," explained Dr. Jan Delphendahl, Chairman of the Supervisory Board of Viromed Medical AG. Christian Strauch has a degree in business administration ("Diplom-Kaufmann") and has many years of experience and a proven track record in building and expanding companies within the healthcare sector. He also has an international network of contacts with decision-makers in the development, manufacturing and distribution of healthcare products. His professional career includes, among other things, more than ten years as a member of the management board of the mail-order pharmacy apo-rot, where he ultimately held the position of managing director. He was also the founder of Linsentaxi GmbH and Pauls Praxis GmbH, as well as the founder and managing partner of pharmedix GmbH. Most recently, he was managing partner of Vameda GmbH, a holding company for corporate investments in the healthcare sector. Uwe Perbandt, former sole member of the Management Board of Viromed Medical AG, added: "I am very much looking forward to working with Christian Strauch in the future. With his experience and contacts, he will actively support and assist me in the next steps of Viromed's growth. This will enable me to focus more on my core competencies and together we can lead the company to success." About Viromed Medical AG: Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG is pursuing the goal of further advancing the use of CAP in medicine in the coming years and realizing the corresponding growth potential.
Contact Viromed Medical AG Uwe Perbandt
03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Viromed Medical AG |
Flensburger Straße 18 | |
25421 Pinneberg | |
Germany | |
Phone: | +49 4101 809960 |
E-mail: | kontakt@viromed-medical.de |
Internet: | https://www.viromed-medical-ag.de/ |
ISIN: | DE000A3MQR65 |
WKN: | A3MQR6 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg |
EQS News ID: | 2043367 |
End of News | EQS News Service |
|
2043367 03.12.2024 CET/CEST
Nachrichten zu Fonterelli SPAC 2 AG Inhaber-Akt
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, buy (EQS Group) | |
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, buy (EQS Group) | |
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, Kauf (EQS Group) | |
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, Kauf (EQS Group) | |
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, buy (EQS Group) | |
17.12.24 |
EQS-DD: Viromed Medical AG: Uwe Perbandt, Kauf (EQS Group) | |
11.12.24 |
EQS-Adhoc: Viromed Medical AG strebt umfangreiche Kooperation mit einem weltweit agierenden Großkonzern an (EQS Group) | |
11.12.24 |
EQS-Adhoc: Viromed Medical AG seeks extensive cooperation with a major global Group (EQS Group) |
Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt
Die Assetklasse Private Debt erklärt | BX Swiss TV
Private Debt: Die rasant wachsende Anlageklasse mit grossem Potenzial für Investoren und Unternehmen!
Im Experteninterview mit Kirsten Bode von Muzinich & Co und Olivia Hähnel von der BX Swiss erfahren Sie, warum Private Debt eine spannende Alternative zur traditionellen Kreditfinanzierung ist. Die Anlageklasse ermöglicht Investoren eine sinnvolle Diversifikation, bietet attraktive Illiquiditätsprämien und zeichnet sich durch eine geringe Volatilität aus. Gleichzeitig profitieren mittelständische Unternehmen von flexiblen Finanzierungslösungen, um Wachstum und Projekte voranzutreiben. Insbesondere in Europa hat sich der Markt in den letzten zehn Jahren verdreifacht und bietet über neue Fondsmodelle auch Privatanlegern Zugang. 2025 könnte ein entscheidendes Jahr für Private Debt werden – dank sinkender Zinsen und steigender Nachfrage. Ein absolutes Muss für alle, die ihre Anlagestrategie um zukunftsträchtige Optionen erweitern wollen!
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Notenbanken im Blick: SMI beendet Handel höher -- DAX schliesst tiefer -- US-Börsen mit Abgaben -- Märkte in Fernost letztlich im MinusAm Dienstag war der heimische Markt auf Richtungssuche, während sich der deutsche Leitindex tiefer zeigte. Die US-Börsen notierten am Dienstag im Minus. Die asiatischen Indizes tendierten unterdessen im Minus.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |